Why Is TEMPUS AI INC A (TEM) Stock Moving Today?

Why TEM stock is down today

Tempus AI Inc A (TEM) fell 13.85% to $71.98 in early trading on October 6, 2026, marking a sharp reversal in a stock already down 14.8% over the previous eight sessions. The move followed the announcement of an expanded multi-year collaboration with Moderna and Merck to build the Sample-to-Sequencing workflow for the experimental cancer vaccine intismeran autogene (V940/mRNA-4157). While the partnership signals long-term potential, it appears to have triggered a sell-off as investors reassessed the company's near-term prospects and capital allocation.

What Happened

Tempus announced an expanded collaboration with Moderna and Merck to support potential commercialization of the individualized neoantigen therapy V940. The agreement is multi-year in duration and aims to prepare for the possible commercial launch of the treatment. However, the stock opened at $71.57, slightly below the prior close, and quickly drifted lower, hitting a session low of $69.56. The stock briefly bounced to a high of $74.94 in the first 30 minutes of trading but failed to hold that level. The session ended with the stock at $70.48, with 0.3 million shares traded, well below the 3-month average.

Separately, BTIG downgraded Personalis, citing the likelihood of a $1.5 billion acquisition by Tempus. This added to the day's volatility as investors considered the broader implications of Tempus's strategic direction and capital use.

What The Data Shows

Over the past 90 days, insiders have sold 26 times, totaling $86.5 million, with the most recent filing on September 29. The stock has printed 64 fresh 52-week lows on October 6, while also hitting seven 52-week highs. Options activity showed unusual put premium of $456,000, with the largest single print at $350,000. The stock currently trades within its 52-week range of $40.77 to $104.32 and has a market cap of $15.1 billion. Despite a 50.4% year-to-date revenue increase, the company remains unprofitable with a net margin of -17.8% and an earnings per share (TTM) of -1.43.

What To Watch

Investors should monitor Tempus’s upcoming earnings report if scheduled, as well as the breadth of analyst coverage and further developments in its partnership with Moderna and Merck.

Why is TEM stock moving today?

TEMPUS AI INC A (TEM) is drawing unusual attention today. Our newswire has captured 3 stories on TEM across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100). The most recent driver: "tempus AI Inc Class A call volume above normal and directionally bullish" (The Fly).

Is TEM a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of TEM coverage reads 57/100 over 3 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.